Jupiter Neurosciences Inc. (JUNS), a clinical-stage biopharmaceutical company, on Wednesday announced entry into a security purchase agreement.
Shares fell to a 52-week low of $0.17 on Wednesday.
The company entered the agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.
Gross proceeds from the offering are estimated to be $2 million.
The offering is expected to close on or about May 21, 2026, subjected to customary closing conditions.
Pipeline Development
Jupiter is currently advancing JOTROL, a proprietary resveratrol formulation for the treatment of Parkinson's disease in a Phase 2a trial. The company also commercializes Nugevia, a consumer longevity supplement, and recently acquired licensing rights to ALA-002 MDMA therapy, a psychedelic drug candidate.
JUNS closed Wednesday at $0.20, down 35.94%. In the overnight market, shares are trading at $0.27, up 31.22%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.